InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol ("CBN"), will report financial results on Thu...
GlobeNewswire · 3d ago
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021
GlobeNewswire · 5d ago
InMed Pharma files applications to evaluate INM-755 for epidermolysis bullosa
InMed Pharmaceuticals (INM) has filed Clinical Trial Applications (CTAs) in Austria, Israel and Serbia as part of a Phase 2 study of INM-755 (cannabinol) cream in Epidermolysis Bullosa ((EB)).Additional CTAs
Seekingalpha · 04/28 12:45
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 Cream in a Phase 2 Trial for Epidermolysis Bullosa
Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 cream   Additional submissions slated for France, Germany, Greece, and Italy over the next several days and
Benzinga · 04/28 11:58
BRIEF-Inmed Pharmaceuticals Submits Clinical Trial Applications To Evaluate INM-755 Cream In Phase 2 Trial For Epidermolysis Bullosa · 04/28 11:41
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
All common shares will continue to be listed and tradable on the NasdaqVANCOUVER, British Columbia, April 27, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabin...
GlobeNewswire · 04/27 12:30
BRIEF-Inmed Pharmaceuticals Announces Voluntary Delisting From TSX · 04/27 11:35
58 Biggest Movers From Yesterday
Benzinga · 04/27 09:03
BRIEF-Inmed Pharmaceuticals Achieves 2G/L Cannabinoid Yield With Integrasyn · 04/26 11:37
The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 04/20 12:06
WRAPUP 1-Asia's rising coronavirus cases a worry as vaccine doubts cloud campaigns · 04/08 08:48
Ontario Lottery and Gaming Corporation - MidDay lottery winning numbers - March 17, 2021
TORONTO, March 17, 2021 /CNW/ - Wednesday 17/03/2021PICK-2: 7 0 PICK-3: 7 8 5 PICK-4: 1 9 4 5 ENCORE: 6681006 DAILY KENO 1, 5, 8, 10, 14, 16, 22, 34, 35, 40, 44, 45, 49, 50, 52, 56, 57, 59, 64, 69.SOURCE OLG WinnersView original content: http://www.
CNW Group · 03/17 19:49
InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) (TSX: IN) Completes $4.5M PIPE Transaction
Mar 15, 2021 (Investor Brand Network via COMTEX) -- InMed Pharmaceuticals (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing...
Investor Brand Network · 03/15 13:46
BRIEF-Inmed Pharmaceuticals Inc Files Prospectus Relates To Offering And Resale By Selling Shareholders Of Up To 1.7 Mln Of Common Shares · 03/05 21:11
InMed to Present at Virtual Conferences in March 2021
GlobeNewswire · 03/03 23:00
IIROC Trading Halt - TTO.H
26, 2021 /CNW/ - The following issues have been halted by IIROC: Company: Atoro Capital Corp.H All Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 7:49 AM IIROC can make a decision to impose a temporary suspension (halt) of tra...
CNW Group · 02/26 13:00
InMed Announces Closing of US$4.5 Million Private Placement
16, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabino...
CNW Group · 02/16 12:30
InMed Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 11, 2021 / InMed Pharmaceuticals, Inc. (TSX:IN) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on February 11, 2021 at 11:30 AM Eastern Time.
ACCESSWIRE · 02/11 14:30
BRIEF-InMed Pharma Reports Second Quarter Fiscal 2021 Financial Results · 02/11 14:06
InMed Pharmaceuticals reports Q4 results
InMed Pharmaceuticals (INM): Q4 GAAP EPS of -$0.37.Cash, cash equivalents and short-term investments of $10.1M.Press Release
Seekingalpha · 02/11 12:42
Webull provides a variety of real-time INM stock news. You can receive the latest news about InMed Pharmaceuticals Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INM
InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).